What question did this study set out to answer?

This research aims to compare the effectiveness of daptomycin and linezolid in treating intra-abdominal infections caused by vancomycin-resistant enterococci with concomitant bacteremia.

March 31, 2026Open Access

Comparative Outcomes of Daptomycin and Linezolid in Vancomycin-resistant Enterococcal Intra-abdominal Infections with Bacteremia

Key Points

This research aims to compare the effectiveness of daptomycin and linezolid in treating intra-abdominal infections caused by vancomycin-resistant enterococci with concomitant bacteremia.
Conducted a multicenter observational study from April 2010 to October 2024.
Included patients with vancomycin-resistant enterococci bloodstream infections and documented intra-abdominal infections treated with daptomycin or linezolid.
Primary outcome measured was 28-day in-hospital mortality.
Daptomycin and linezolid showed no significant difference in 28-day mortality (29.5% vs. 37.1%; P =0.42).
Daptomycin ≥11 mg/kg was associated with reduced mortality (adjusted odds ratio 0.29; P =0.03), while lower dosages did not show significant effects.
Independent predictors of mortality included higher Pitt bacteremia score, lower platelet count, and presence of malignancy.

Abstract

• The medicinal options to treat intraabdominal infection (IAI) caused by vancomycin-resistant enterococci (VRE) remain limited. • This study provides evidence that daptomycin is comparable with linezolid to treat VRE-IAI with bloodstream infection, and daptomycin ≥11 mg/kg is associated with better survival. Vancomycin-resistant enterococci (VRE) are pathogenic in intra-abdominal infections (IAI). Although daptomycin (8–12 mg/kg) is effective for VRE bloodstream infections (BSI), evidence supporting its use in VRE-IAI remains limited. We conducted a multicenter observational study. Between April 2010 and October 2024, we screened all patients with VRE-BSI and included those with a documented VRE-IAI treated with daptomycin or linezolid. Limiting enrollment to patients with concurrent bloodstream infections reduced misclassification bias. The primary outcome was 28‑day in‑hospital mortality. Of 184 patients included, 149 received daptomycin and 35 received linezolid. Most patients (98.3%) underwent source control procedures. A total of 96 patients (52.2%) had hepatobiliary IAI, while 88 (47.8%) had non-biliary IAI. The 28-day mortality did not differ significantly between daptomycin and linezolid groups (29.5% vs. 37.1%; P =0.42). Multivariable logistic regression identified the independent predictors of mortality including higher Pitt bacteremia score (adjusted odds ratio 95% confidence interval, 1.22 1.06–1.41; P =0.006), lower platelet count (0.97 0.94–0.99; P =0.02), and malignancy (2.41 1.10–5.25; P =0.03). Daptomycin was not associated with increased mortality compared with linezolid (adjusted odds ratio 95% confidence interval, 0.63 0.28–1.44; P =0.27). Daptomycin ≥11 mg/kg was linked to reduced mortality (adjusted odds ratio 95% confidence interval, 0.29 0.09–0.91; P =0.03), whereas daptomycin 8–11 mg/kg showed no significant difference (0.79 0.34–1.85; P =0.59). Findings were consistent in augmented inverse probability weighting analysis. Daptomycin is comparable with linezolid for treating VRE-IAI and BSI, with daptomycin ≥11 mg/kg associated with improved survival. Further investigations are warranted given a small sample size.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper